Patents by Inventor Romain Siegrist

Romain Siegrist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOBUTYL-UREA DERIVATIVES
    Publication number: 20230303486
    Abstract: The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.
    Type: Application
    Filed: June 24, 2021
    Publication date: September 28, 2023
    Inventors: Olivier BEZENCON, Caroline DEYMIER, Jens-Uwe PETERS, Romain SIEGRIST, Jean-Philippe SURIVET
  • SPIROUREA DERIVATIVES
    Publication number: 20230136562
    Abstract: The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing one or more compounds of Formula (I), and to the use of such compounds as medicaments, especially as Kv7 openers.
    Type: Application
    Filed: April 27, 2021
    Publication date: May 4, 2023
    Inventors: Olivier BEZENCON, Caroline DEYMIER, Jens-Uwe PETERS, Romain SIEGRIST, Jean-Philippe SURIVET
  • Crystalline forms
    Patent number: 10351560
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 16, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist, Markus Von Raumer
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 10301309
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 28, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Triazole compounds as T-type calcium channel blockers
    Patent number: 10246426
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 2, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Olivier Bezencon, John Gatfield, Bibia Heidmann, Romain Siegrist, Simon Stamm
  • CRYSTALLINE FORMS
    Publication number: 20190047996
    Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Idorsia Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST, Markus VON RAUMER
  • Pyrazole compounds and their use as T-type calcium channel blockers
    Patent number: 10065929
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 4, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon
  • TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20180230109
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: September 14, 2015
    Publication date: August 16, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Olivier BEZENCON, John GATFIELD, Bibia HEIDMANN, Romain SIEGRIST, Simon STAMM
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20180105520
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 19, 2018
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20180105496
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: December 19, 2017
    Publication date: April 19, 2018
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain SIEGRIST, Bibia HEIDMANN, Simon STAMM, John GATFIELD, Olivier BEZENCON
  • Pyrazole compounds and their use as T-type calcium channel blockers
    Patent number: 9932314
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: April 3, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Romain Siegrist, Bibia Heidmann, Simon Stamm, John Gatfield, Olivier Bezencon
  • Azaindole acetic acid derivatives and their use as prostaglandin Dreceptor modulators
    Patent number: 9879006
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 30, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9850241
    Abstract: The present invention relates to azaindolle acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: December 26, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170129884
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 17, 2015
    Publication date: May 11, 2017
    Applicant: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • Acrylamide derivatives as antimalarial agents
    Patent number: 9637473
    Abstract: The invention relates to novel acrylamide derivatives of the formula I wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Claire-Lise Ciana, Thierry Kimmerlin, Romain Siegrist
  • PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20170096399
    Abstract: The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 6, 2017
    Inventors: Romain SIEGRIST, Bibia HEIDMANN, Simon STAMM, John GATFIELD, Olivier BEZENCON
  • AZAINDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    Publication number: 20170022196
    Abstract: The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Application
    Filed: March 16, 2015
    Publication date: January 26, 2017
    Inventors: Hamed AISSAOUI, Christoph BOSS, Patrick BOUIS, Julien HAZEMANN, Romain SIEGRIST
  • Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9255090
    Abstract: The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 9, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Hamed Aissaoui, Christoph Boss, Sylvia Richard-Bildstein, Romain Siegrist
  • NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS
    Publication number: 20160024050
    Abstract: The invention relates to novel acrylamide derivatives of the formula (I) wherein R1, R2, R3, X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Hamed AISSAOUI, Christoph BOSS, Claire-Lise CIANA, Thierry KIMMERLIN, Romain SIEGRIST
  • 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
    Patent number: 9169270
    Abstract: The present invention relates to 1-phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Y, Z, R1, R2, R3 and R4 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    Type: Grant
    Filed: July 4, 2013
    Date of Patent: October 27, 2015
    Assignee: Actelion Pharmaceuticals Ltd.
    Inventors: Hamed Aissaoui, Christoph Boss, Sylvia Richard-Bildstein, Romain Siegrist